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Abstract
Aim. To agree a draft pressure ulcer risk factor Minimum Data Set to underpin
the development of a new evidenced-based Risk Assessment Framework.
Background. A recent systematic review identified the need for a pressure ulcer
risk factor Minimum Data Set and development and validation of an evidenced-
based pressure ulcer Risk Assessment Framework. This was undertaken through
the Pressure UlceR Programme Of reSEarch (RP-PG-0407-10056), funded by the
National Institute for Health Research and incorporates five phases. This article
reports phase two, a consensus study.
Design. Consensus study.
Method. A modified nominal group technique based on the Research and
Development/University of California at Los Angeles appropriateness method.
This incorporated an expert group, review of the evidence and the views of a
Patient and Public Involvement service user group. Data were collected December
2010–December 2011.
Findings. The risk factors and assessment items of the Minimum Data Set
(including immobility, pressure ulcer and skin status, perfusion, diabetes, skin
moisture, sensory perception and nutrition) were agreed. In addition, a draft Risk
Assessment Framework incorporating all Minimum Data Set items was
developed, comprising a two stage assessment process (screening and detailed full
assessment) and decision pathways.
Conclusion. The draft Risk Assessment Framework will undergo further design
and pre-testing with clinical nurses to assess and improve its usability. It will then
be evaluated in clinical practice to assess its validity and reliability. The
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Introduction
Pressure Ulcers (PUs) are associated with ill health and poor
mobility and have a detrimental effect on patients’ quality
of life (Gorecki et al. 2009, 2012). They are defined as
‘localized injury to the skin and/or underlying tissue usually
over a bony prominence, as a result of pressure, or pressure
in combination with shear’ and are numerically classified
according to the severity of the ulcer and the tissue layers
involved (National Pressure Ulcer Advisory Panel/European
Pressure Ulcer Advisory Panel (NPUAP/EPUAP 2009). PUs
remain a substantial problem (Schoonhoven et al. 2007,
Vowden & Vowden 2009, Pieper 2012) and present a
financial burden to healthcare organisations worldwide
(Severens et al. 2002, Bennett et al. 2004, Schuurman et al.
2009, Berlowitz et al. 2011, Dealey et al. 2012).
Why is this research or review needed?
• There are limitations associated with development methodologies and content validity
for risk assessment scales and a lack of agreement of the risk factors required to ade-
quately identify risk.
• A recent systematic review highlighted the need to agree a pressure ulcer risk factor
Minimum Data Set to facilitate meta-analysis and underpin risk assessment.
What are the key findings?
• Consensus methods facilitated agreement of a pressure ulcer risk factor Minimum
Data Set incorporating nine risk factors and associated assessment items.
• The development of a draft pressure ulcer Risk Assessment Framework incorporating
the Minimum Data Set in preparation for pre-testing and clinical evaluation.
How should the findings be used to influence policy/practice/research/
education?
• The Minimum Data Set could be used by healthcare professionals to record key
pressure ulcer risk factors, facilitating clinical risk assessment, case mix adjustment,
multivariable analyses and future meta-analysis.
• The draft pressure ulcer Risk Assessment Framework is being further evaluated to
assess its reliability and validity in preparation for eventual long-term implementation
in clinical practice.
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Background
In clinical practice PU risk assessment is considered key to
prevention (AHCPR 1992, NICE 2003, NPUAP/EPUAP
2009) and despite limited evidence of clinical effectiveness
risk assessment tools/scales are routinely used. These incor-
porate the assessment of PU risk factors and usually use a
scoring system to allocate the patients level of risk, e.g.
‘high risk, moderate risk, at risk’.
There are several limitations associated with development
methodologies, content validity and evaluation of PU risk
assessment scales. ‘Gold standard’ methods include multi-
variable modelling (either from single studies or meta-
analysis from a number of studies) to identify items for a
risk tool, with subsequent model testing on a ‘new’ pro-
spective target population (Steyerberg 2010). The majority
of risk assessment tools have been developed using non-sys-
tematic reviews of the epidemiological literature and expert
opinion (Cullum et al. 1995, Nixon & McGough 2001)
with postdevelopment evaluation of reliability and validity
(Beeckman et al. 2012).
Where ‘gold standard’ methods have been used in tool
development methodological limitations are apparent
including the use of single rather than multiple centre popu-
lations and inadequate sample sizes for both model deriva-
tion and testing (Suriadi et al. 2008, Slowikowski & Funk
2010, Page et al. 2011). The development and predictive
validity testing of PU risk assessment scales is further com-
plicated by:
• the absence of a reference standard for PU ‘risk’ with
‘PU presence’ being commonly used as an alternative
despite their differences (Kottner & Balzer 2010).
• the instigation of preventative interventions being a key
element of standard clinical practice which will impact
tool performance in the study population (Deeks 1996,
Defloor & Grypdonck 2004).
There are also practical problems associated with the use
of existing risk assessment scales. While many were
designed for use on patients without PUs to identify those
at ‘risk’, they are in practice often used for all patients (i.e.
those with and without PUs) and they do not differentiate
between these two groups. Furthermore, in clinical practice
risk assessment and skin assessment are viewed as two sep-
arate processes. This is a limitation for two reasons. Firstly,
nurses may disregard the presence of an existing PU in clin-
ical assessment and fail to initiate appropriate secondary
prevention and treatment interventions, leading to the pro-
gression of a severe PU (Pinkney et al. 2014). Secondly, our
risk factor systematic review indicated that alterations to
intact skin and the presence of a category 1 PU are key pre-
dictors of subsequent ≥category 2 PUs (Coleman et al.
2013). Another issue is that a full detailed risk assessment
is undertaken on all patients even those who are clearly not
at risk. This unnecessarily diverts nursing time away from
other priorities. There is a need, therefore to streamline the
assessment process to incorporate a screening stage that
would allow those who are obviously ‘not at risk’ to be
quickly identified, preventing the need for a more detailed
full assessment.
We therefore embarked on a work package to develop
and validate a robust risk assessment tool to facilitate the
assessment and stratification of PU risk in adult patient
populations. This was undertaken as part of the PU Pro-
gramme Of reSEarch (PURPOSE: RP-PG-0407-10056),
funded by the National Institute for Health Research
(NIHR) and comprised five distinct phases:
1 a systematic review of the existing evidence to identify
risk factors associated with increased probability of PU
development (Coleman et al. 2013)
2 a consensus study to agree a draft risk factor Minimum
Data Set (MDS) to underpin the development of a Risk
Assessment Framework (RAF)
3 the proposal of a new PU conceptual framework building
on the phase 2 consensus study (Coleman et al. 2014)
4 the design and pre-testing of the draft RAF with clinical
nurses to assess and improve usability
5 the clinical evaluation of the RAF to assess reliability,
validity, data completeness and clinical usability
Phase one the systematic review, provided the foundation
for the work (Coleman et al. 2013). The review comprised
54 eligible studies (34,449 patients) and identified a large
number of potential risk factors (15 domains, 46 sub-do-
mains including over 250 named variables), lack of
comparable data fields for measurement of the same
constructs and key risk factors not being routinely recorded
in all studies (Coleman et al. 2013). Due to these
limitations, meta-analysis was not possible and a narrative
synthesis was undertaken.
The narrative synthesis of the systematic review found
that the most consistently emerging risk factor domains
were immobility, skin/PU status and perfusion (including
diabetes). Other important but less consistently emerging
risk factor domains included nutrition, moisture, age, hae-
matological measures, general health status, sensory percep-
tion and mental status (Coleman et al. 2013). A small
number of studies suggest a relationship between body tem-
perature and immunity and PU development and these fac-
tors require further confirmatory research. The evidence
© 2014 The Authors. Journal of Advanced Nursing Published by John Wiley & Sons Ltd. 2341
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regarding race and gender was equivocal (Coleman et al.
2013). While immobility assessment is included in existing
PU risk assessment tools, the inclusion of skin/PU status
and perfusion (including diabetes) is not universal.
The systematic review highlighted the need to re-consider
which risk factors should be considered in PU risk assess-
ment, how these should be assessed and the overall assess-
ment process. In addition, a key recommendation of the
review was the development of a risk factor MDS, to encour-
age the use of consistent risk factors across PU studies facili-
tating large scale multivariable analysis, meta-analysis and
case mix adjustment (Berlowitz et al. 2001). It was also pro-
posed that to enable the routine recording of the MDS in
practice, the MDS would be incorporated into the RAF. This
paper reports phase two of the work, the consensus study.
The study
Aim
To develop a draft PU risk factor Minimum Data Set
(MDS) and Risk Assessment Framework (RAF) for pre-test-
ing and clinical evaluation. The objectives were:
• To agree a list of patient characteristics to form an
MDS suitable for routine collection of key risk factors
in adult patient populations.
• To develop a RAF incorporating the MDS with:
(a) a simple screening stage to quickly identify not at
risk patients
(b) a detailed full assessment stage for patients who
are at potential/actual risk or have an existing PU
(c) Decision pathways, i.e. not currently at risk, pri-
mary prevention (at risk) or secondary prevention
and treatment pathway (with PU).
Design
A consensus study involving a modified nominal group
technique based on the RAND/UCLA (Research and
Development/University of California at Los Angeles)
appropriateness method (Fitch et al. 2001) was used. This
incorporated face-to-face interaction of an expert group
and pre- and postmeeting questionnaire completion. In
addition, face-to-face interaction of a Patient and Public
Involvement (PPI) service user group (PU Research Service
User Network: PURSUN) to consider the acceptability of
proposed risk assessment elements was undertaken. The
face-to-face element of the methodology was considered
necessary due to the complexity of the subject area.
Sample/participants
The expert group comprised internationally recognized clin-
ical/academic leaders identified via their publication record
in PU or relevant research. The group was purposively sam-
pled to include the perspectives of nurses (academic and
clinical nurse specialists), doctors (diabetologist, vascular
surgeon, elderly care medicine and public health), bioengi-
neers, epidemiologist and individuals with organisational
development and clinical decision-making expertise. A
multi-specialty group was developed to take account of a
wide range of opinions (Hutchings & Raine 2006). Seven-
teen members were recruited to allow for attrition, as 12
was considered the optimum number in relation to prevent-
ing co-ordination problems while maximizing reliability
(Murphy et al. 1998).
The service user group, involved members of PURSUN
UK (web address: http://www.pursun.org.uk/), which was
set up to improve the quality of PPI in PU research. Seven
members were involved in the study and included people
with direct experience of a PU, people with experience of
living with PU risk and carers.
Data collection
Data collection was undertaken December 2010–December
2011. The consensus process incorporated an initial expert
group meeting and an initial PURSUN meeting, followed
by two consensus cycles. The first consensus cycle focussed
on agreeing the risk factors to be included in the MDS and
RAF, while the second consensus cycle focussed on agreeing
the assessment items. Each cycle comprised an expert group
face-to-face meeting and pre- and postmeeting consensus
questionnaire completion (Figure 1). A PURSUN meeting
was also undertaken at the end of cycle 1 (Figure 1).
Reviewing the PU risk factor evidence was an important
element of the study and was integrated throughout all
cycles of the consensus process. The systematic review,
through its identification of risk factor domains and sub-
domains provided the foundation for considering which risk
factor variables were important for identifying PU risk.
Other wider scientific evidence was also drawn from the
expertise of the group. The relevance of the evidence to
clinical practice and the practicalities of PU risk assessment
were also considered.
Questionnaires were completed by all expert group mem-
bers privately before and after cycle 1 and 2 meetings
(Figure 1). This allowed individuals to change their ratings
in light of discussions and/or where necessary for question-
naire items to be clarified and amended. In each question-
2342 © 2014 The Authors. Journal of Advanced Nursing Published by John Wiley & Sons Ltd.
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naire participants were asked to rate their level of support
for statements (relating to the inclusion of risk factors/
assessment items to the MDS and RAF) on a 9-point Likert
scale where 1 indicated strong disagreement and 9 indicated
strong agreement (Figure 2). Each statement was preceded
by summaries of the PU systematic review evidence, expert
group discussions, PURSUN group discussions (as applica-
ble) and follow-up/explanatory notes (as applicable). Elec-
tronic links to the full systematic review evidence tables
and the full summary of the preceding expert group discus-
sions were also available in the questionnaires. Question-
naires were administered and completed via a commercial
online survey platform.
All expert group meetings were led by trained facilitators
and were audio-taped. Unlike a traditional RAND/UCLA
method where the first face-to-face meeting occurs follow-
ing questionnaire completion, an initial face-to-face meeting
was undertaken to review the PU evidence and consider the
views of the group. This informed the development of the
cycle 1 risk factor questionnaire (Raine et al. 2005). At
cycle 1 and 2 expert group meetings (Figure 1), the pre-
meeting collective questionnaire responses were anony-
mously fed back to the group. Members were also provided
with a reminder report of their individual questionnaire
responses and a copy of the summary of the previous expert
group meeting discussions. The questionnaire results high-
lighted areas of agreement and areas of uncertainty and dis-
agreement. This provided a focus for the group discussions
to ascertain whether there was genuine uncertainty or dis-
agreement, or if there was ambiguity in the wording of the
questionnaire.
As PU risk assessment practice is part of routine care
there was a need to explore the acceptability of proposed
risk assessment elements with patients and carers. This was
undertaken through facilitated PURSUN meetings. At







Cycle 1 post-expert 
group meeting 
questionnaire completion 
Cycle 1 expert group 
face-to-face meeting 




PU Risk Factors 
Cycle 2 post-expert 
group meeting 
questionnaire completion 
Cycle 2 expert group 
face-to-face meeting 





Figure 1 Overview consensus cycle.
Statement Relating to Immobility
After reviewing the above evidence please indicate your level of agreement with the following statement.
Data item(s)/clinical measure(s) 
relating to immobility status 
should be recorded for use at the 
screening stage of the PU risk 









Figure 2 Example questionnaire items from the cycle 1 questionnaire.
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introduced to the aims of the study, the purpose of the
meetings and discussed potential assessment components of
the MDS and RAF. Views were fed back to the expert
group by the Patient and Public Involvement Officer (cycle
1). At the second PURSUN meeting (cycle 1, Figure 1)
members were asked to consider the risk factors that the
expert group had agreed should be included in the MDS
and RAF, potential assessment items and the acceptability
of collecting this information on a routine basis. Views
were fed back to the expert group via the cycle 2 pre-meet-
ing questionnaire (which included a summary PURSUN
discussions) prompting discussion at the expert group
meeting.
Ethical considerations
The study was reviewed and approved by a University
Research Ethics Committee. Informed consent was gained
from expert group members prior to participation and they
remained free to withdraw from the study without giving
reasons.
Data analysis
The researcher (SC) listened to the audio-tapes and read the
associated transcripts in total to ensure completeness. The
data were coded with categories based on the PU risk factor
systematic review, in keeping with a directed content
analysis approach (Hsieh & Shannon 2005). As new themes
were identified from the expert group discussions, further
codes were added. A summary report of each meeting was
generated by the researcher (SC). The report was reviewed
by the facilitators and members of a working group
(sub-group of expert group) to ensure it reflected group
discussions.
Careful notes were taken throughout the PURSUN meet-
ings and a summary of discussions was written by the
researcher (SC). The summary was circulated to the facilita-
tor and group participants to ensure it reflected the discus-
sions of the meeting.
Questionnaire statements were summarized using the
median group response as a measure of central tendency. In
keeping with the RAND/UCLA Appropriateness methods
and other studies (Scott & Black 1991, Fitch et al. 2001,
Shiffman et al. 2003, Kroger et al. 2007) Likert scale group
median responses for each statement were categorised into
3 tertiles. For this study the categories were 1–3 disagree,
4–6 uncertain, 7–9 agree. Within-group agreement was
measured using the RAND Disagreement index (Fitch et al.
2001), which considers the dispersion of individual scores
and identifies areas of disagreement (where panellists rate
at both ends of the Likert Scale). This involves calculating
the interpercentile range (IPR: 03–07) and the IPR
adjusted for symmetry (IPRAS) to detect disagreement (if
the IPR is larger than the IPRAS there is disagreement)
(Fitch et al. 2001). By calculating the ratio of these an
index of >1 indicates disagreement.
Using the group median response and the disagreement
index for each statement (about risk factors/assessment
items) the following principles were applied following post-
meeting questionnaire completion (Figure 1):
• Group medians of 1–3 without disagreement would be
excluded
• Group medians of 7–9 without disagreement would be
included
• Where the disagreement index was >1 or where the
median was 4–6 they would be excluded but are poten-
tial areas for further research.
Validity and reliability
It has been recognized that it is difficult to determine the
validity of consensus judgements (i.e. whether ‘good judge-
ments’ are made) at the time the judgements are made
(Black et al. 1999). It is, therefore, important that the con-
sensus process is as rigorous as possible (Raine et al. 2005).
This study applied principles of good practice in the plan-
ning and delivery of the consensus process incorporating
the involvement of a mixed-speciality expert group (Hutch-
ings & Raine 2006) and the views of service users (PUR-
SUN). Other key principles included careful preparation
and consideration of relevant evidence throughout the con-
sensus process, questionnaire content informed by expert
group discussions (and reviewed by a working group to
ensure content validity), private completion of question-
naires by expert group members, facilitated face-to-face
meetings and the inclusion of a measure of dispersion and
central tendency in the reporting (Black et al. 1999). While
the reliability of expert group judgements were not assessed
in this study, future work is being planned to check the rep-
resentativeness of the expert group views with the wider
community (Raine et al. 2005).
Results
The expert group comprised of 17 international experts in
the PU field, comprising nine female and eight male partici-
pants. There was 100% completion of all questionnaires
and 86% attendance at the face-to-face meetings (17 of 17
attended the first meeting, 13 of 17 attended the second
2344 © 2014 The Authors. Journal of Advanced Nursing Published by John Wiley & Sons Ltd.
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meeting and 14 of 17 attended the third meeting). The
results concerning the risk factors (cycle 1) and assessment
items (cycle 2) of the MDS and RAF are detailed below.
Cycle 1: risk factors
The expert group agreed that three risk factors should be
incorporated into the screening stage of the MDS and RAF
for the assessment of all patients and comprised immobility,
existing and previous PU. Table 1 indicates the question-
naire responses before and after the expert group meetings.
In the pre-meeting questionnaire responses there was sup-
port for inclusion of three risk factors and exclusion of 13
risk factors, with uncertainty for 10 risk factors (three with
disagreement). Following the consensus meeting and discus-
sion of the areas of uncertainty and disagreement the post
meeting questionnaire responses indicated agreement for
inclusion of three risk factors and exclusion of 21 risk fac-
tors (Table 1).
The expert group agreed that eleven risk factors, namely
immobility, existing and previous PU, general skin status,
perfusion, skin moisture, dual incontinence, diabetes, sen-
sory perception, nutrition and albumin should be incorpo-
rated into the detailed full assessment stage of the MDS
and RAF. This would be for patients, who were considered
to be at potential/actual risk or have an existing PU from
the screening stage. Table 2 indicates the questionnaire
responses before and after the expert group meetings. In the
pre-meeting questionnaire responses there was support for
inclusion of 12 risk factors and exclusion of two risk fac-
tors, with uncertainty for 12 risk factors (two with dis-
agreement). Following the consensus meeting and
discussion of the areas of uncertainty and disagreement the
postmeeting questionnaire responses indicated agreement
for inclusion of 11 risk factors, exclusion of 4 risk factors
and uncertainty for nine risk factors (1 with disagreement)
(Table 2). After reviewing the evidence the postmeeting
questionnaire was revised and Blood Pressure (BP), smoking
and cardiovascular disease were combined into a general
category of ‘perfusion’. A summary of the key discussion
points relating to the uncertain risk factors is detailed in
Table 3.
Using the decision rules highlighted in the methods sec-
tion, the MDS and RAF comprised only those risk factors
where there was agreement (group median 7-9 without dis-
agreement). The progression of risk factors through the
consensus study are detailed in Figure 3 (also see Tables 2
and 3). This shows that of the original 15 risk factor
domains and 46 sub-domains of the systematic review
(Coleman et al. 2013), 26 risk factors were considered to
potentially warrant inclusion in the MDS and RAF and
progressed to consensus cycle 1.
The risk factors for inclusion were mainly agreed in the
cycle 1 postmeeting questionnaire but there were some
refinements of the risk factors in the cycle 2 pre-meeting
questionnaire. The expert group recognized that albumin
emerged strongly in the systematic review and that it was
important in relation to potential changes in oncotic pres-
sure and the development of oedema. Some also thought it















Immobility status 900 000 900 000
Existing pressure
status
900 013 900 000
Previous PU
status
700 029 800 029
General skin
status
500 187* 300 074
Sensory perception 400 068 300 072
Acute illness 500 059 300 054
Infection 500 098 200 033
Body temperature 500 097 200 029
Nutrition 500 055 200 075
Friction and shear 200 016 200 029
Chronic wounds 300 065 200 029




200 020 200 013
Perfusion – – 200 075
Albumin 300 048 200 029
Skin moisture 400 161* 200 029
Dual
incontinence
500 170* 200 033
Medication 300 033 100 002
Mental status 200 065 100 013
Age 400 067 100 016
Race 200 049 100 002
Gender 100 029 100 002
Haemoglobin 200 037 100 016
Pitting oedema 300 067 100 013
BP 300 067 – –
Smoking 200 037 – –
Cardiovascular
disease
300 067 – –
Dark grey: group median 1–3 (inclusion not supported).
Mid grey: group median 4–6 (uncertain).
Light grey: group median 7–9 (inclusion supported).
*Disagreement.
© 2014 The Authors. Journal of Advanced Nursing Published by John Wiley & Sons Ltd. 2345
JAN: ORIGINAL RESEARCH Developing a PU risk factor MDS and RAF
was linked to nutritional status. The expert group agreed
that albumin should be included at the second stage of the
assessment (Table 2). However, at a subsequent PURSUN
meeting, concern was raised about the need to undertake
an additional blood test for assessment of albumin. This
concern was fed back to the expert group in the cycle 2
pre-meeting questionnaire. Members were asked whether
there was a clinical indication for undertaking an additional
blood test to measure albumin to establish level of PU risk.
It was concluded that this was unnecessary and it would
not be included in the MDS and RAF. The expert group
also concluded that skin moisture and dual incontinence
could be combined into one measure.
Cycle 2: assessment items for risk factors
There was good support (group median 7–9 without dis-
agreement) for all statements in the cycle 2 questionnaire
concerning the assessment items of MDS and RAF. How-
ever, following group discussion at the cycle 2 meeting, it
was said that some changes were necessary to specific items.
As the group were content with the majority of the PU risk
factor MDS items highlighted in the cycle 2 pre-meeting
questionnaire, the postmeeting questionnaire focussed on
items that required adjustment. The agreed assessment
items for the screening and detailed full assessment stage
are shown in Table 4. In addition, the expert group agreed
that the RAF would facilitate the identification of a risk
profile for each patient, rather than condense the risk from
different aspects into a single score. This would support
care planning with interventions selected in response to spe-
cific risk factors.
Draft RAF
Using the results from cycle 1 and 2 of the study an initial
draft of the RAF (Figure 4) was made incorporating the
screening and detailed full assessment stage and decision
pathways of the assessment, i.e. not currently at risk, pri-
mary prevention (at risk) or secondary prevention and
treatment pathway (existing PU or scarring from a previous
PU). This will undergo further graphic design in prepara-
tion for pre-testing.
Discussion
Using structured consensus methods, the risk factors and
assessment items for a draft MDS and RAF were agreed.
The consensus methods were particularly useful in allowing
us to identify the risk factors for inclusion in the RAF and
MDS. While they were also useful in identifying the key
principles of the assessment items, the method was inappro-
priate for considering the specific wording of items. Of note
was the agreement that the risk factors and assessment
items should be the same for the MDS and the RAF, i.e. no
additional risk factor information to supplement the MDS
was considered necessary for a RAF for assessment in clini-
cal practice. The draft RAF differs from other risk assess-
ment tools in two main ways. First, the incorporation of a
screening stage allows those who are obviously ‘not at risk’
to be quickly identified preventing the need for a more
















Immobility status 900 016 900 000
Existing PU status 900 013 900 016
Previous PU status 700 040 800 016
General skin status 800 023 800 029
Skin moisture 800 029 800 033
Diabetes 800 029 800 033
Nutrition 700 067 800 016
Perfusion – – 800 040
Albumin 700 020 700 045
Sensory perception 800 029 700 029
Dual incontinence 800 019 700 033
Friction and shear 500 110* 600 052
Chronic wounds 600 042 600 037
Medication 500 041 500 008
Acute illness 700 007 500 059
Infection 500 110* 500 041
Body temperature 700 052 500 088
Pitting oedema 600 030 500 104*




400 062 400 065
Haemoglobin 500 032 300 072
Mental status 500 072 200 075
Race 200 049 100 013
Gender 200 029 100 002
BP 500 052 – –
Smoking 500 059 – –
Cardiovascular
disease
600 042 – –
Dark grey: group median 1–3 (inclusion not supported).
Mid grey: group median 4–6 (uncertain).
Light grey: group median 7–9 (inclusion supported).
*Disagreement.
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Table 3 Uncertain risk factors.
Uncertain risk factors Key discussion points
Friction and shear • Important concept in relation to biomechanics and tissue loading
• Debate about whether a patient characteristic
• Difficult to measure in practice
• Different definition of terms (e.g. nurses and bioengineers)
• Interlinked with immobility





• Felt to be important clinically
• Links between the 3 elements recognized
• Impact on mobility, perfusion and moisture acknowledged
Chronic wound • Did not emerge as a strong risk factor in the systematic review
• Link to other factors including nutritional depletion, moisture(exudate), oedema,
diabetes and general skin condition recognized
• Would be captured by other key risk factors e.g. general ‘skin status’, nutrition, moisture and diabetes
Pitting oedema • Relatively unexplored area in the literature
• Leads to changes in the mechanical properties of the tissues
• May result in reduced mobility due to heavy oedematous legs
• Some felt that oedema should be considered under the skin status umbrella
Medication • Acknowledged that the systematic review evidence associated with medication was weak.
• Links between specific medications and risk factors were made, e.g. the effects of sedation,
epidurals and analgesia on sensation and movement and steroids on skin condition (tissue paper skin)
• Use of vasoconstrictors in specialist areas important
• Complicated by dose-dependent effects
• Difficult to measure
Age • Some felt that age formed an important element of assessment
• Others felt it was a proxy for other measures e.g. skin condition and immobility
15 Risk factor domains
and 46 sub-domains of the
systematic review  reduced to 26





4. General skin status
5. Chronic wound



































Cycle 1: Risk factor post-
meeting questionnaire
1. Immobility
2. Existing  PU
3. Previous PU













2. Existing  PU
3. Previous PU









of MDS and RAF
Full Assessment Stage
Immobility










PU Status (existing and
previous)
Figure 3 Risk factor progression.
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detailed full assessment, which will save time in clinical
practice. Second, the integration of the skin assessment
items enables the identification of vulnerable skin or an
existing PU (and/or scarring from a previous PU) to be a
key consideration in the risk assessment and subsequent
care planning. Where a PU is identified, the patient will be
allocated to the secondary prevention and treatment path-
way, which has the potential to facilitate escalation of
interventions to prevent deterioration and promote healing.
Further research is required to confirm this.
The use of the systematic review evidence (Coleman et al.
2013) provided the foundation for the evidence base of the
consensus study. The expert group also considered wider
scientific evidence, clinical and practical implications and
the views of PURSUN when deciding which risk factors
should be included at the screening stage and the detailed
full assessment stage of the MDS and RAF. This enabled
the expert group to agree the key risk factors to summarize
patient risk, i.e. those that were considered to increase the
probability of PU development. However, it was recognized
that other excluded risk factors may still have a role in the
PU causal pathway via their relationship with the primary
risk factors and may be important at an individual patient
level, e.g. the use of inotropes have an impact on perfusion.
PU causal pathways were considered more closely in a fol-
low-up piece of work which proposes a new conceptual
framework (Coleman et al. 2014).
The risk factors included in the MDS and RAF included
those with strong epidemiological evidence (immobility,
existing PU, general skin status, perfusion (including diabe-
tes), and those with less consistent epidemiological evidence
which were felt to be important in clinical practice (mois-
ture, nutrition, sensory perception). Previous PU was
included on the basis of clinical and service user opinion
and theoretical bioengineering evidence, rather than by the
epidemiological evidence. Conversely, albumin, which has
strong epidemiological evidence was initially agreed for
inclusion in the MDS and RAF by the expert group, but
was subsequently excluded due to concerns raised by PUR-
SUN. In these examples, where the group diverged from the
epidemiological evidence the reasons were in keeping with
some of those previously reported including clinical experi-
ence and patient preference (Raine et al. 2004).
There was strong commitment from the expert group to
be involved throughout the study, though there were a few
occasions where participants were unable to attend the face-
to-face meetings (13/17 attended the second meeting and 14/
17 attended the third meeting). On these occasions, special
arrangements were made to ensure they were properly
updated and could continue to participate in the process.
One to one telephone meetings were organized between the
researcher and these individuals after the expert group
meeting. The participant was sent the same information
Table 4 MDS (to be incorporated in RAF).
Screening Stage
Mobility:
a. Does the patient walk without help?
b. Does the patient change position?
PU status:
a. Current PU (≥1 category)
b. Reported history of PU
Detailed Full Assessment stage





Immobility items to incorporate the magnitude of independent
movement, e.g.:
a. Doesn’t move
b. Slight position changes
c. Major position changes
Immobility items to incorporate general, clinically relevant
descriptions of movement, e.g.:
a. Bedfast
b. Chairfast
c. Walks with assistance
Sensory perception:
a. Does the patient feel and respond appropriately to
discomfort from pressure
PU (existing and previous PU):
a. Category of PU (where possible for previous PU)
b. Site of PU
c. Presence of scar tissue (for previous PU)
General skin status:
a. Confirmation of vulnerable skin, e.g. dryness, paper thin
and redness
b. Pressure area skin site
Perfusion:
a. Conditions affecting central circulation, e.g. shock, heart
failure and hypotension
b. Conditions affecting peripheral circulation, e.g. peripheral
vascular/arterial disease.
Diabetes:
a. Presence of diabetes
Moisture:
a. Presence of moisture due to perspiration, urine, faeces or
exudate.
Frequency:
b. Frequent (1 or 2 times a day)
c. Constant
Nutrition:
a. Unplanned weight loss
b. Poor nutritional intake
c. Low BMI
d. High BMI
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considered at the expert group meeting and the researcher
presented the same power point presentations and summa-
rized the discussions of the expert group meeting. The partic-
ipant then completed the online questionnaire (all completed
the pre-meeting questionnaires at the same time as the rest of
the group). Every effort was made to ensure that these partic-
ipants remained engaged in the consensus process but there
remains the possibility that these participants might have
made different questionnaire responses had they been subject
to the actual expert group discussions.
The integration of the PURSUN perspective throughout
the study proved invaluable and to our knowledge is the first
study to use such an approach. While others using consensus
methods have incorporated patient/carer representation to
their expert groups (Rycroft-Malone 2001, Jackson et al.
2009) we decided to use an alternative approach when devel-
oping the study methodology. This was due to concern that
the complexity of the epidemiological and wider scientific
evidence, and the complex nature of facilitating a mixed
group of patients and professionals could have impeded the
patients and carers input into the process. Difficulties in
involving patients and carers in the development of technical
and clinical guidelines have been raised previously (Rolls &
Elliott 2008). For this study, there seemed to be more value
in devoting whole meetings to patient/carer insights, with
particular emphasis on the acceptability of elements of assess-
ment. This allowed us to consider the views of a larger num-
ber of service users. We were conscious of the need to
integrate PURSUN members’ perspectives into the consensus
process. This was achieved by feedback at the expert group
meetings or inclusion of their comments into questionnaires,
so that the group could consider the patient/carer perspective
alongside other evidence.
Limitations
While the study involved an expert group with considerable
experience a weakness of the methodology relates to reli-
ability and whether the results of this study are representa-
tive of the views of other experts in the field. This could
prove especially important for uncertain areas such as fric-
tion and shear (excluded) where the expert group identified
a close relationship with immobility and difficulties in mea-
suring this risk factor in clinical practice. Raine, Sanderson
and Black proposed a new approach in developing clinical
guidelines which includes checking the representativeness of
the group’s ratings with a large similarly composed group
(Raine et al. 2005). With this in mind, further work is
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Figure 4 Draft RAF with underpinning MDS.
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currently being planned to consider the risk factors that
should be considered in the MDS and RAF with a larger
group. This will also allow new evidence to be brought for-
ward and integrated into the work.
While the consensus study provided us with a draft MDS
and RAF further development is underway. This incorpo-
rates further liaison with the expert group and PURSUN, and
the subsequent phases of the work package (conceptual
framework proposal, design, pre-testing and clinical evalua-
tion of the RAF). Of particular note is that the design and
pre-test will address issues of usability, clarification of areas
of confusion and guidance for decision-making of assessment
outcomes. It will also facilitate the development of a User
Manual to accompany the RAF where assessment compo-
nents and operational definitions can be fully explained. This
was considered important by the expert group who recog-
nized areas of practice where operational definitions are
vague, for example in the assessment of general skin status.
The pre-test will also prepare the RAF for clinical evaluation
where further assessment of reliability and validity can be
undertaken. In the longer-term future large scale statistical
modelling will be undertaken to refine the RAF.
Conclusion
Using a modified nominal group technique based on the
RAND/UCLA appropriateness method, incorporating an
expert group, review of the PU evidence and the views of a
PPI service user group (PURSUN) we have agreed risk fac-
tors, assessment items and have drafted the MDS and RAF.
The RAF comprises two stages of assessment, the screening
stage for all patients and the detailed full assessment stage
for patients at potential/actual risk or with an existing PU.
The RAF allows patients to be allocated to a not currently
at risk, primary prevention (at risk) or secondary preven-
tion and treatment pathway (existing PU or scarring from a
previous PU).
The continuing development of the RAF is being to be
taken forward by the NIHR funded programme of research
(PURPOSE: RP-PG-0407-10056). This involves further
design and pre-testing of the RAF with clinical nurses, and
evaluation in clinical practice. It is hoped that this will give
an up-to-date, valid and reliable tool for use with adult
populations in clinical practice. Further testing will be
needed to assess if this translates to better care and reduced
PU incidence or severity. The MDS will encourage the use
of consistent risk factors across PU studies facilitating meta-
analysis and case mix adjustment. In addition, the MDS
will allow further statistical modelling to be undertaken to
refine the RAF.
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